[go: up one dir, main page]

WO2009028629A1 - 複素環化合物およびその用途 - Google Patents

複素環化合物およびその用途 Download PDF

Info

Publication number
WO2009028629A1
WO2009028629A1 PCT/JP2008/065454 JP2008065454W WO2009028629A1 WO 2009028629 A1 WO2009028629 A1 WO 2009028629A1 JP 2008065454 W JP2008065454 W JP 2008065454W WO 2009028629 A1 WO2009028629 A1 WO 2009028629A1
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic compound
formula
disclosed
substituents
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/065454
Other languages
English (en)
French (fr)
Inventor
Masaaki Hirose
Masanori Okaniwa
Yoko Hayashi
Terufumi Takagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to JP2009530185A priority Critical patent/JP5350247B2/ja
Priority to EP08828528.3A priority patent/EP2184285B1/en
Priority to US12/675,663 priority patent/US8344135B2/en
Priority to TW097145882A priority patent/TW201004620A/zh
Priority to PE2008002012A priority patent/PE20091259A1/es
Priority to ARP080105279A priority patent/AR069567A1/es
Publication of WO2009028629A1 publication Critical patent/WO2009028629A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

　本発明は、強力なＲａｆ阻害活性を示す下式複素環化合物を提供する。式（ＩＩＩ） 〔式中、各置換基の定義は本文中と同意義を示す。〕で表される化合物またはその塩。
PCT/JP2008/065454 2007-08-29 2008-08-28 複素環化合物およびその用途 Ceased WO2009028629A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2009530185A JP5350247B2 (ja) 2007-08-29 2008-08-28 複素環化合物およびその用途
EP08828528.3A EP2184285B1 (en) 2007-08-29 2008-08-28 Heterocyclic compound and use thereof
US12/675,663 US8344135B2 (en) 2007-08-29 2008-08-28 Heterocyclic compound and use thereof
TW097145882A TW201004620A (en) 2008-07-18 2008-11-27 Heterocyclic compound and use thereof
PE2008002012A PE20091259A1 (es) 2008-07-18 2008-12-03 Compuestos heterociclicos como inhibidores de raf quinasa
ARP080105279A AR069567A1 (es) 2008-07-18 2008-12-04 Compuestos heterociclicos que tienen una fuerte actividad inhibidora de raf y son utiles para el tratamiento preventivo y similares del cancer y sus usos

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-223284 2007-08-29
JP2007223284 2007-08-29
JP2008187953 2008-07-18
JP2008-187953 2008-07-18

Publications (1)

Publication Number Publication Date
WO2009028629A1 true WO2009028629A1 (ja) 2009-03-05

Family

ID=40387343

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/065454 Ceased WO2009028629A1 (ja) 2007-08-29 2008-08-28 複素環化合物およびその用途

Country Status (4)

Country Link
US (1) US8344135B2 (ja)
EP (1) EP2184285B1 (ja)
JP (1) JP5350247B2 (ja)
WO (1) WO2009028629A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064611A1 (ja) * 2008-12-01 2010-06-10 武田薬品工業株式会社 複素環化合物およびその用途
US8143258B2 (en) 2008-12-02 2012-03-27 Takeda Pharmaceutical Company Limited Benzothiazole compounds useful for Raf inhibition
US8304557B2 (en) 2007-06-05 2012-11-06 Takeda Pharmaceutical Company Limited Fused heterocycle derivatives and use thereof
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
US8501936B2 (en) 2009-06-05 2013-08-06 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
JP2016520617A (ja) * 2013-05-30 2016-07-14 カラ ファーマシューティカルズ インコーポレイテッド 新規の化合物及びその使用
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100926804B1 (ko) 2004-04-30 2009-11-12 리서치 인 모션 리미티드 데이터 전송을 처리하기 위한 시스템 및 방법
US20110003809A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
EP2265574A1 (en) * 2008-02-29 2010-12-29 Array Biopharma, Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
CL2009000447A1 (es) * 2008-02-29 2010-01-04 Array Biopharma Inc Y Genentech Inc Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf.
AU2009222144A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Pyrazole [3, 4-b] pyridine Raf inhibitors
WO2011144742A1 (en) 2010-05-21 2011-11-24 Chemilia Ab Novel pyrimidine derivatives
PT2580322T (pt) * 2010-06-09 2018-03-01 Dana Farber Cancer Inst Inc Uma mutação em mek1 que confere resistência aos inibidores de raf e mek
AU2012230229A1 (en) 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
WO2012148792A1 (en) * 2011-04-26 2012-11-01 Merck Sharp & Dohme Corp. Heterocyclic compounds as b-raf inhibitors for treatment of cancer
US9161226B2 (en) 2011-10-17 2015-10-13 Blackberry Limited Associating services to perimeters
US9497220B2 (en) 2011-10-17 2016-11-15 Blackberry Limited Dynamically generating perimeters
US9613219B2 (en) 2011-11-10 2017-04-04 Blackberry Limited Managing cross perimeter access
US8799227B2 (en) 2011-11-11 2014-08-05 Blackberry Limited Presenting metadata from multiple perimeters
US9369466B2 (en) 2012-06-21 2016-06-14 Blackberry Limited Managing use of network resources
GB2508792A (en) * 2012-09-11 2014-06-18 Rec Modules Pte Ltd Back contact solar cell cell interconnection arrangements
US20140280698A1 (en) * 2013-03-13 2014-09-18 Qnx Software Systems Limited Processing a Link on a Device
WO2016086026A1 (en) 2014-11-26 2016-06-02 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof
CN105884628B (zh) * 2016-06-06 2018-06-29 上海工程技术大学 2,4-二叔丁基-5-氨基酚的制备方法
EP3877371A4 (en) * 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
CN115996917B (zh) 2020-05-06 2025-10-28 艾捷斯治疗公司 作为jak2抑制剂的6-杂芳基氧基苯并咪唑和氮杂苯并咪唑
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
TW202325289A (zh) 2021-11-09 2023-07-01 美商雅捷可斯治療公司 Ｊａｋ２抑制劑之形式及組合物
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN114805120A (zh) * 2022-05-23 2022-07-29 江苏瑞达环保科技有限公司 一种间氰甲基苯甲酸甲酯的合成工艺
US20240199546A1 (en) * 2022-10-12 2024-06-20 Maze Therapeutics, Inc. Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof
US12145945B2 (en) 2023-03-10 2024-11-19 Breakpoint Therapeutics Gmbh Compounds, compositions, and therapeutic uses thereof
CN119119096B (zh) * 2024-09-09 2025-09-16 郑州药领医药科技有限公司 一种4-((4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)甲基)哌啶-1-甲酸叔丁酯的合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044156A2 (en) * 2000-11-29 2002-06-06 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
WO2003082272A1 (en) * 2002-03-29 2003-10-09 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
WO2005032548A1 (en) * 2003-09-29 2005-04-14 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
WO2007030377A1 (en) * 2005-08-30 2007-03-15 Novartis Ag Substituted benzimidazoles as kinase inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21048A (en) * 1858-07-27 holzer
US4237300A (en) 1975-12-09 1980-12-02 Merck & Co., Inc. Certain 6-substituted-2-pyridinamines
US4177274A (en) 1975-12-09 1979-12-04 Merck & Co., Inc. Substituted imidazo [1,2-a] pyridines
US4096264A (en) 1975-12-09 1978-06-20 Merck & Co., Inc. Certain substituted imidazo [1,2-a] pyridines
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP1017384B1 (en) * 1997-09-26 2004-11-10 Zentaris GmbH Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
AU2001235838A1 (en) 2000-03-06 2001-09-17 Smithkline Beecham Plc Imidazol derivatives as raf kinase inhibitors
EP1318992B1 (en) 2000-09-21 2005-07-27 Smithkline Beecham Plc Imidazole derivatives as raf kinase inhibitors
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
US20040192689A1 (en) 2001-09-05 2004-09-30 Dean David Kenneth Heterocycle-carboxamide derivatives as raf kinase inhibitors
WO2003022838A1 (en) 2001-09-05 2003-03-20 Smithkline Beecham Plc Pyridine substituted furan derivatives as raf kinase inhibitors
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
JP4604086B2 (ja) 2004-05-07 2010-12-22 エグゼリクシス， インコーポレイテッド Ｒａｆモジュレーターおよびその使用方法
KR20060079098A (ko) * 2004-12-31 2006-07-05 주식회사 엘지생명과학 신규한([1,3]티아졸로[5,4-ｂ]피리딘-2-일)-2-카르복사마이드유도체
WO2006076376A1 (en) 2005-01-11 2006-07-20 Medicinova, Inc. Topical treatment of solid tumors and ocular neovascularization
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
KR20070052207A (ko) 2005-11-16 2007-05-21 주식회사 엘지생명과학 신규한 ｋｄｒ 억제제
US8304557B2 (en) 2007-06-05 2012-11-06 Takeda Pharmaceutical Company Limited Fused heterocycle derivatives and use thereof
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044156A2 (en) * 2000-11-29 2002-06-06 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
WO2003082272A1 (en) * 2002-03-29 2003-10-09 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
WO2005032548A1 (en) * 2003-09-29 2005-04-14 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
WO2007030377A1 (en) * 2005-08-30 2007-03-15 Novartis Ag Substituted benzimidazoles as kinase inhibitors

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304557B2 (en) 2007-06-05 2012-11-06 Takeda Pharmaceutical Company Limited Fused heterocycle derivatives and use thereof
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
WO2010064611A1 (ja) * 2008-12-01 2010-06-10 武田薬品工業株式会社 複素環化合物およびその用途
US8143258B2 (en) 2008-12-02 2012-03-27 Takeda Pharmaceutical Company Limited Benzothiazole compounds useful for Raf inhibition
US8497274B2 (en) 2008-12-02 2013-07-30 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8501936B2 (en) 2009-06-05 2013-08-06 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
US8633173B2 (en) 2009-06-05 2014-01-21 Cephalon, Inc Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
JP2016520617A (ja) * 2013-05-30 2016-07-14 カラ ファーマシューティカルズ インコーポレイテッド 新規の化合物及びその使用
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Also Published As

Publication number Publication date
EP2184285B1 (en) 2015-11-04
US20100249119A1 (en) 2010-09-30
JP5350247B2 (ja) 2013-11-27
US8344135B2 (en) 2013-01-01
JPWO2009028629A1 (ja) 2010-12-02
EP2184285A1 (en) 2010-05-12
EP2184285A4 (en) 2011-07-20

Similar Documents

Publication Publication Date Title
WO2009028629A1 (ja) 複素環化合物およびその用途
WO2009028655A1 (ja) 複素環化合物およびその用途
WO2009025358A1 (ja) 複素環化合物およびその用途
WO2009030469A8 (en) Fungicidal 2-alkylthio-2-quinolinyloxy-acetamide deritvatives
WO2008130021A3 (en) Heterocyclic hydrazide compound and pesticidal use of the same
WO2009049716A8 (en) Novel fungicides
WO2008110355A8 (en) Quinoline derivatives as fungicides
WO2009048101A1 (ja) アミド化合物
WO2009019015A8 (en) Novel herbicides
WO2009087098A3 (en) Quinoline derivatives and their use as fungicides
MY150989A (en) Benzothiazole compounds useful for raf inhibition
WO2009041705A3 (en) 5-membered heterocyclic compounds as proton pump inhibitors
WO2008102908A1 (ja) ハロアルキルスルホンアニリド誘導体
WO2009024342A3 (en) Novel microbiocides
WO2006058700A8 (en) Acetamide compounds as fungicides
EP1953145A4 (en) HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY OF 11-HYDROXYSTEROID DEHYDROGENASE TYPE I
WO2009060835A8 (ja) 新規ユビキリン結合性小分子
WO2010063700A3 (en) Novel pyrazole-4 -n-alkoxycarboxamides as microbiocides
WO2009019005A3 (en) Tricyclic bridged cyclopentanedione derivatives as herbicides
WO2009007115A8 (en) Tropane derivatives useful as pesticides
WO2008151828A8 (en) Novel microbiocides
WO2009030467A8 (en) Saturated and insaturated bi- or tricyclic aryloxyacetamide derivatives and their use as fungicides
WO2008136385A1 (ja) アミド化合物およびその用途
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2009018925A8 (en) Herbicide triazolylpyridine ketones

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828528

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009530185

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12675663

Country of ref document: US

Ref document number: 2008828528

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE